5 news items
Candel Therapeutics Receives FDA Orphan Drug Designation For CAN-2409 For The Treatment Of Pancreatic Cancer
CADL
11 Apr 24
, with no dose-limiting toxicities and no cases of pancreatitis. Analysis of resected tumors showed treatment with CAN-2409 modified the tumor
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
CADL
4 Apr 24
toxicities, including no cases of pancreatitis.
Price Action: CADL shares are up 31.70% at $2.21 on the last check Thursday.
Photo via Shutterstock
Candel Therapeutics Announces Interim Data From Randomized Phase 2 Clinical Trial Of CAN-2409 In Non-Metastatic Pancreatic Cancer
CADL
4 Apr 24
, providing further support that multiple injections of CAN-2409 were generally well tolerated, with no dose-limiting toxicities and no cases
Candel Therapeutics (NASDAQ: CADL) Lead Product Candidate CAN-3110 Demonstrates Promise To Treat Deadly Brain Tumors
CADL
15 Mar 24
of all, local delivery enables Candel to achieve these results while aiming to minimize systemic toxicity
Moving Fast: Candel's (NASDAQ: CADL) CAN-3110 Granted FDA Fast Track Designation For Recurrent High-Grade Glioma Following Fast Track Designation For CAN-2409 In Pancreatic Cancer
CADL
28 Feb 24
-limiting toxicity reported. The investigators observed a near-doubling of the expected median overall survival (mOS) after a single CAN-3110 injection
- Prev
- 1
- Next